Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nimotuzumab plus gemcitabine versus placebo plus gemcitabine in chemotherapy-naive advanced pancreatic cancer
2007-000338-38Phase 2Completed
- Sponsor
- Oncoscience AG
- Start
- Apr 2007
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in pancreatic cancer (PC) comparing Theraloc + gemcitabine with Placebo + gemcitabine (2 arms). Primary endpoints: Time to tumor progression and Overall survival. Started Apr 2007; status: completed.
02
Drugs
nimotuzumab
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on 2007-000338-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-000338-38.